Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 22, 2026 03:30 ET | Source: STORM Therapeutics

STORM Therapeutics to Present Promising Phase 1 Sarcoma Data Demonstrating Activity of First‑in‑Class METTL3 Inhibitor STC‑15 at ASCO 2026

STORM Therapeutics announces that a subset analysis of sarcoma patients enrolled in the Phase 1 dose escalation study of STC-15 will be presented at ASCO.
May 21, 2026 16:05 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation

REDWOOD CITY, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...
May 21, 2026 13:30 ET | Source: Custom Market Insights

[Latest] Global Genome Editing Market Size/Share Worth USD 55.7 Billion by 2035 at a 17.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, May 21, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Genome Editing Market Size, Trends and Insights By Technology (CRISPR)/Cas9,...
May 21, 2026 07:30 ET | Source: EDAP TMS S.A.

EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference

, May 21, 2026 (GLOBE NEWSWIRE) -- EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference Company to Present and Host 1x1 Investor Meetings on Thursday, June 4th, 2026 AUSTIN,...
May 20, 2026 11:17 ET | Source: Leafwell, Inc.

Leafwell Advances Medical Cannabis as Clinically Validated Solution for Cancer-Related Symptoms and Chronic Pain, Supports Employer-Sponsored Mental Health Benefits

Leafwell Advances Medical Cannabis as Clinically Validated Solution for Cancer-Related Symptoms and Chronic Pain, Supports Employer-Sponsored Mental Health
May 20, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade

These findings reinforce the importance of continuing to deepen our understanding of the underlying biology that drives both growth and resistance.
May 19, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients

After a thorough process, management are pleased to undertake this pivotal step for GMP production of PRP for the upcoming Phase 1 FIH clinical study
May 19, 2026 08:02 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities

OCALA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced a significant increase in stockholder equity and that the Company has...
May 18, 2026 07:00 ET | Source: Byondis B.V.

Byondis Establishes Scientific Advisory Board of Recognized Leaders in Oncology Research and ADC Development

Global experts in antibody-drug conjugate (ADC) development, oncology clinical development and early-phase trial design, appointed to support advancement of Byondis’ differentiated ADC pipeline and a...
May 18, 2026 02:00 ET | Source: Byondis B.V.

Byondis Establishes Scientific Advisory Board of Recognized Leaders in Oncology Research and ADC Development

Global experts in antibody-drug conjugate (ADC) development, oncology clinical development and early-phase trial design, appointed to support advancement of Byondis’ differentiated ADC pipeline and a...